Vaccines against traveler's diarrhoea and rotavirus disease - A review

Wiener Klinische Wochenschrift, Supplement

Volumn 118, Issue 3, 2006, Pages 2-8

  Wiedermann, Ursula ^a   Kollaritsch, Herwig ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Diarrheal disease; ETEC; Rotavirus; Vaccination

Indexed keywords

CHOLERA TOXIN; CHOLERA VACCINE; PLACEBO; ROTAVIRUS VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; ENTEROTOXIGENIC ESCHERICHIA COLI; GASTROENTERITIS; HUMAN; MORBIDITY; MORTALITY; REVIEW; ROTAVIRUS; SALMONELLA; TRAVELLER DIARRHEA; VACCINATION; VIRUS INFECTION; VIRUS TRANSMISSION;

ADULT; AUSTRIA; CHILD; DEVELOPING COUNTRIES; DYSENTERY; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TRAVEL;

EID: 33846362285     PISSN: 03005178     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-006-0671-5     Document Type: Review

References (46)

1. Steffen R, Castelli F, Nothdurft HD, Rombo L, Zuckerman JN (2005) Vaccination against enterotoxigenic Escherichia coli, a cause of Traveler's diarrhoea. J Travel Med 12: 102-107
2. Yates J (2005) Traveler's diarrhoea. American Family Physician 71: 2075-2100; 2107-2108
3. Parashar UD, Hummelman EG, Bresee JC, Miller MA, Glass RI (2003) Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 9: 565-572
4. Quadri F, Ahmed T, Ahmed F, Bhuiyan NA, Rahman AS, Clemens JD, Black RE, Albert MJ (2003) Safety and immunogenicity of an oral inactivated enerotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine 21: 2394-2403
5. Hall ER, Wierzba TF, Ahren C, Rao MR, Bassily S, Francis W, Girgis FY, Safwat M, Lee YJ, Svennerholm AM, Clemens JD, Savarino SJ (2001) Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral killed enterogenic Escherichia coli plus cholera toxin B subunit vaccine. Infect Immun 9: 2853-2857
6. Wiedermann G, Kollaritsch H, Kundi M, Svennerholm AM, Bjare U (2000) Double-blind, randomized, placebo controlled pilot study evaluating effciacy and reactogenicity of an oral ETEC B-subunit inactivated whole cell vaccine against traveler's diarrhoea (preliminary report). J Travel Med 7: 27-29
7. Jertborn M, Ahre C, Holmgren J, Svennerholm AM (1998) Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine. Vaccine 16: 225-260
8. Boedecker E.C. (2005) Vaccines for enterotoxigenic Escherichia coli: current status. Curr Opin Gastroenterol 21: 15-19
9. Katz D, De Lorimier A, Wolf M, Hall ER, Cassels FJ, van Hamont JE, Newcomer RL, Davachi MA, Taylor DN, McQueen CE (2003) Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6. Vaccine 21: 341-346
10. Lasaro MO, Luiz WB, Sbrogio-Altmeida ME, Ferreiria LCS (2005) Prime-boost vaccine regime confers protective immunity to human derived enterotoxigenic Escherichia coli. Vaccine 23: 2430-2438
11. Clemens JD, Sack DA, Harris JR, Chakraborty J, Neogy PK, Stanton B, Huda N, Khan MU, Kay BA, Khan MR (1988) Cross-protection by B-subunit-whole cell cholera vaccine against diarrhoea associated with heat-labile toxin producing enterotoxigenic Escherichia coli: result from a large scale field trial. J Infect Dis 158: 372-377
12. Peltola H, Siitonen A, Kyrönseppä H, et al (1991) Prevention of travellers' diarrhoea by oral B-subunit/whole cell cholera vaccine. Lancet 338: 1285-1289
13. Scerpella EG, Sanchez JL, Mathewson III JJ, et al (1995) Safety, immunogenicity and protective efficacy of the whole-cell/recombinant B-subunit (WC/rBS) oral cholera vaccine against travelers' diarrhoea. J Travel Med 2: 22-27
14. Jiang ZD, Okhuysen PC, Guo DC, et al (2003) Genetic susceptibility to enteroaggregative Escherichia coli diarrhoea: polymorphism in the interleukin-8 promoter region. J Infect Dis 188: 506-511
15. Holmgren J, Bergquist Ch (2004) Oral B subunit-killed whole cell cholera vaccine. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (eds) New generation vaccine, 3rd edn. Marcel Dekker, 499-509
16. Roberts L (2004) Rotavirus vaccines' second chance. Science 305: 1890-1893
17. World Health Report WHR (2004) www.who.int/whr/ 2004/annex/topic/en/ annex_2_en.pdf
18. Glass RI, Bresee JS, Parashar U, Turcios R, Fischer TK, Jiang B, Widdowson MA, Gentsch J (2005) Rotavirus vaccines: past, present and future. Arch de pediatric 12: 844-847
19. Grimwood K, Abbot GD, Fegusson DM, Fergusson DM, Jennings LC, Allan JM (1983) Spread of rotaviurs within families: a community based study. BMJ 287: 575-577
20. Dennehy RH (2004) Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis 19: S103-105
21. Waters V, Ford-Jones L, Petric M, Jennings LC, Allan JM (2000) Etiology of community acquired pediatric viral diarrhoea: a prospective longitudinal study in hospitals, emergency departments, pediatric practices and child care centers during the winter rotavirus outbreak, 1997-1998. Pediatr Infect Dis J 19: S843-848
22. Velazquez FR, Matson DO, Calva JJ (1996) Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335: 1022-1028
23. Cunliffe NA, Nakagoni O (2005) A critical time for rotavirus vaccines: a review. Expert Rev Vaccines 4: 521-532
24. Rotavirus: www.brown.edu/courses/bio160/Projects2004/ rotavirus/Rotashield.htm
25. Santos N, Hoshino Y (2005) Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15: 29-56
26. Koshimura Y, Nakaoni T, Nakagoni O (2000) The relative frequency of G serotypes of rotaviruses recovered from hospitalized children with diarrhoea: a 10 years survey (1987-1996) in Japan with a review of global collection data. Microbiol Immunol 44: 499-510
27. Vesikari T, Mäki M, Isolauri E (1983) Epidemiologic background for the need of rotavirus vaccine in Finland: preliminary experience of RIT 4237 strain of live attenuated rotavirus vaccine in adults. Dev Biol Standard 53: 229-236
28. Senturia YD, Peckham CS, Cordery M, Chrystie IA, Banatvala JE, Andre FE (1987) Live attenuated oral rotavirus vaccine. Lancet 2: 1342-1345
29. Vesicari T, Giaquinto C, Huppertz HI (2006) Clinical trials of rotavirus vaccines in Europe. Pediatr. Infect Dis J 25: S542-S547
30. Joensun J, Koskenniemi E, Pang XL, Vesikari T (1997) Randomized placebo-controlled trial of rhesus-human reassortant rotaviurs vaccine for prevention of severe rotavirus gastroenteritis. Lancet 350: 1205-1209
31. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA (1995) Evaluation of rhesus rotavirus monovalent and tretravalent reassortant vaccines in US children. JAMA 273: 1191-1196
32. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, Mack ME, Davidson BL, Kapikian AZ (1996) Safety and efficacy of high dose rhesus-human reassortant rotavirus vaccines: report of the National Multicenter Trial. Pediatrics 97: 7-13
33. Center for Disease Control and Prevention (1999) Intussusception among reciepients of rotavirus vaccine. United States 1998-1999. MMWR 48: 577-581
34. Center for Disease Control and Prevention (1999) Withdraw of rotavirus vaccine recommendation. MMWR 48: 1007
35. Bernstein DI, Smith VI, Sherwood JR, Schiff GM, Sander DS, DeFeudis D, Spriggs DR, Ward RL (1998) Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 16: 381-387
36. DeVoss B, Vesikari T, Linhares A, Salinas B, Perez-Schael I, Ruiz-Palacios GM, Guerrero Mde L, Phua KB, Delem A, Hardt K (2004) A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 23: S179-S182
37. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al; Human Rotavirus Vaccine Study Group (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354: 11-22
38. Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, De Vos B (2004) Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 23: 937-943
39. Salinas B, Perez-Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzabal JP, Cervantes Y, Costa Clemens S, Damaso S, Hardt K, De Vos B (2005) Evaluation of safety, immunogenicty and efficacy of an attenuated rotavirus vaccine RIX 4414: a randomized, placebo controlled trial from Latin American infants. Pediatr Infect Dis J 24: 807-816
40. Clark HF, Bernstein DI, Dennehy RH, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ, Laura D, Eiden JJ, Ivanoff N, Kaplan KM, Heaton P (2004) Safety, efficacy and immunogenicity of a live, quadrivalent human-bovine rotavirus vaccine in healthy infants. J Pediatr 144: 184-190
41. Vesikari T, Clark HF, Offit RA, et al (2004) The effect and dose of composition of a pentavalent roatvirus vaccine (Rotateq) upon safety, efficacy and immunogenicity in healthy infants. 22nd annual meeting of the European Society for Pediatric Infectious Diseases (ESPID), Tampere, Finland, May 26-28
42. Vesikari T, Matson DO, Dennehy P, et al; Rotavirus Efficacy and Safety Trial (REST) Study Team (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 344: 23-33
43. Heaton RM, Goveia MG, Miller JM, Offit P, Clark HF (2005) Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 192 [Suppl]: S17-S21
44. Glass RI, Parashar UD (2006) The promise of new rotavirus vaccines. N Engl J Med 354: 75-77
45. Vesikari T, Karvonen A, Prymula R, et al (2006) Human rotavirus vaccine Rotarix® (4414) is highly efficacious in Europe. 24th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Basel, Switzerland, May 3-5
46. Rendi-Wagner P, Kundi M, Mikolasek A, Mutz I, Zwiauer K, Wiedermann U, Vecsei A, Kollaritsch H (2006) Active hospital based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wien Klin Wochenschr 118: 280-285